Find policies, billing codes, payers, states, and providers
Biliopancreatic diversion / duodenal switch (and related bariatric procedures)
Customize your policy alerts
Sign up for Colorado Rocky Mountain Health Plans Policy CS007.X alerts
Get alerted when Policy CS007.X changes without checking for updates manually.
Monitor payer policy activity
Defines Colorado Rocky Mountain Health Plans' medical necessity, coverage rationale, definitions, applicable codes, and documentation expectations for selected bariatric surgical procedures (including biliopancreatic diversion/duodenal switch) for adults and adolescents; excludes specified states listed in the Application. Affects providers seeking coverage for bariatric procedures under this payer policy.
Replaced references to 'Nonalcoholic Fatty Liver Disease (NAFLD)' with 'Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)'.
Revised coverage criteria for a planned two-stage procedure; replaced criterion requiring the 'individual has been compliant with nutrition and exercise' with 'individual has been adherent to nutrition and exercise'.
Updated list of unproven and not medically necessary procedures and replaced terminology grouping (e.g., consolidated gastrointestinal liners, intragastric balloon, endoscopic sleeve gastroplasty under 'transoral endoscopic surgery').
Added CPT code 43889 to the list of applicable CPT codes.
Medical records documentation requirements were updated: added items (e.g., indicate whether request is initial/planned two-stage/revision/removal; preoperative evaluation; physical activity patterns; recent diagnostic testing; physician's treatment plan; for adolescents include obesity class) and replaced several prior documentation items (e.g., 5-year BMI history → 2-year BMI history).
Added several specific procedures to archived/updated lists (e.g., silastic ring vertical gastric bypass; transoral outlet reduction [TORe]).
Coverage Criteria and Evidence Summaries
Adult medical necessity criteria
Covered when ALL of the following are met for adults aged 18 years or older:
All elements required
All elements required
All elements required
Adolescent medical necessity criteria
Covered when ALL of the following are met for adolescents aged 12 to 17 years:
All elements required
All elements required
Planned two-stage procedure
Planned two-stage bariatric procedures are covered when ALL of the following are met:
All elements required
Revisional bariatric surgery indications
Revisional bariatric surgery is covered WHEN due to a technical failure or major complication from the initial procedure (examples listed):
Any listed indication qualifies
Descriptive clinical context (no coverage rules in excerpt)
Policy includes clinical descriptions of obesity, first-line treatments, and multiple bariatric procedures; no explicit coverage decision nodes are present in this excerpt.
No explicit medical-necessity decision logic in this chunk.
Evidence summaries relevant to coverage decisions
Key clinical findings and implications summarized as coverage-relevant statements
Supported by systematic reviews and cohort studies
Leang et al. 2024
Multiple long-term cohort studies
Clapp et al.; long-term cohort evidence
Hayes HTA and systematic reviews
Revisional surgery evidence statements
Evidence-based findings relevant to revisional bariatric surgery:
Supported by Chierici et al., Ataya et al., others
Supported by Dardamanis et al., Sharples et al., Tran et al.
Koh et al. and meta-analytic findings
Pediatric/adolescent surgery evidence statements
Findings relevant to bariatric surgery in adolescents:
Teen-LABS, MBSAQIP analyses, Inge et al., Qi et al.
Alqahtani et al.; systematic review findings
Bariatric artery embolization (investigational)
Status of bariatric artery embolization (TBE):
Reddy et al. 2020 and policy summary
Evidence summaries guiding coverage considerations
Findings and considerations for procedures where coverage decisions depend on available evidence:
Hayes HTA, RCT and cohort data
Parmar et al. 2020 and systematic reviews
Weitzner et al., Abu Dayyeh RCT, ECRI assessments
Evidence considerations for coverage
Evidence-based considerations for coverage determinations
Supported by systematic reviews and RCTs
Chen et al.; REDUCE trial; ReCharge findings
Repeatedly noted limitations across device and procedure reviews
VBLOC (vagus nerve blocking) — evidence considerations
Evidence summary relevant to coverage decisions for VBLOC:
ReCharge and follow-up reports
Apovian et al.; Shikora et al.
Endoscopic bariatric therapies — evidence and guideline-aligned coverage considerations
Endoscopic bariatric therapies (EBTs) and intragastric balloons — guideline and evidence points relevant to coverage:
ASGE PIVI analyses and position statements
AGA recommendations
Coverage criteria mapped to guideline recommendations
Coverage aligned with guideline-based eligibility when criteria below are met
Align prior authorization with guideline thresholds
Endocrine Society and AAP considerations
Endorsements do not imply identical coverage for all procedures; consider evidence quality and patient factors
Clinical guidance and evidence on nutritional complications
Guideline-informed coverage considerations
Guideline and society recommendations summarized; coverage decisions should reflect these elements:
Guideline concordance recommended for authorization
Endocrine Society, SAGES, NICE position statements
IFSO, NICE, ASGE recommendations
This section summarizes coverage-related criteria, evidence considerations, and investigational classifications for multiple bariatric procedures and endoscopic therapies. Revisions to documentation and code lists are reflected in the policy update (see medical records and CPT code changes). The policy distinguishes standard, guideline-endorsed bariatric surgeries from procedures considered investigational or not medically necessary based on current evidence.
Revisional bariatric surgery is addressed as covered only when performed for specific technical failures or major complications of the initial operation; requests for revision for other indications should be assessed against the listed acceptable indications and will require documentation of prior attempts at conservative management and multidisciplinary assessment. The policy explicitly notes that revisional procedures for indications other than those listed are not covered (examples and documentation requirements are specified).
The policy clarifies that the included code lists are for reference only and do not by themselves determine coverage; benefit coverage remains subject to federal/state/contractual requirements and other applicable policies. Providers should follow the updated medical records documentation requirements (including specifying whether the request is for an initial procedure, planned two-stage procedure, revision, or removal; preoperative evaluation; recent diagnostic testing; treatment history; and adolescent-specific items such as obesity class).
Several endoscopic and device-based interventions are identified as investigational or lacking sufficient evidence for routine coverage. These include bariatric artery embolization (transcatheter approaches such as left gastric artery embolization), gastrointestinal liners (EndoBarrier/DJBL) which are not FDA-approved in the U.S. and have high early removal and SAE rates, gastric electrical stimulation (limited early-phase data), laparoscopic greater curvature plication (LGCP) (inferior and less durable weight loss vs LSG), and multiple transoral endoscopic procedures (including endoscopic sleeve gastroplasty/ESG and transoral outlet reduction/TORe) where evidence is limited and comparative long-term outcomes versus standard bariatric surgery are insufficient.
The policy highlights device- and procedure-specific safety signals and trial results that inform coverage considerations: DJBL/EndoBarrier pooled data show substantial early removal (~19%) and SAE incidence (~17%); VBLOC (vagal nerve blocking/Maestro) failed to meet prespecified efficacy objectives in the pivotal ReCharge randomized sham-controlled trial; TBE/LGA embolization evidence is small and methodologically limited (small RCTs and case series); and multiple endoscopic therapies produce less weight loss than laparoscopic sleeve gastrectomy in available studies.
Guideline and technology-assessment guidance is summarized to support clinical decision-making: NICE recommends some devices only in research or special arrangements (e.g., DJBL, swallowable gastric balloon, SADI-S in some contexts); professional society guidance and HTAs note that endoscopic options may be considered adjunctive within multidisciplinary programs but typically yield less weight loss than surgical options and require careful patient selection and monitoring.
Operationally, prior authorization and medical-record review should confirm guideline-based BMI/comorbidity eligibility, multidisciplinary evaluation/referral, documentation of prior conservative therapies, and the specific indication for revision or staged procedures. The updated policy also reorganized the list of unproven/not medically necessary procedures under transoral endoscopic surgery and updated required documentation items and applicable CPT codes (including the addition of CPT 43889).
The policy lists applicable procedure and diagnosis codes for reference but emphasizes that the list is not exhaustive and that inclusion of a code does not imply coverage or guarantee payment. Coverage decisions remain subject to federal/state/contractual requirements and other applicable policies.
Providers should use the listed CPT and unlisted codes when requesting authorization and should include the updated documentation items specified in the policy (e.g., whether the request is initial, planned two-stage, revision, or removal; preoperative evaluation; treatment history). The policy revision notes that code lists were updated to reflect annual edits and other administrative changes.
Gastrointestinal liners (for example, the EndoBarrier/DJBL) are described in the policy as investigational for obesity and type 2 diabetes in routine clinical practice. The EndoBarrier is not approved by the U.S. Food and Drug Administration and is limited by federal law to investigational use only.
Systematic reviews report meaningful short-term weight and glycemic effects with DJBL implantation but also identify high early removal rates (~19%) and substantial serious adverse event rates (~17%) including device migration and gastrointestinal hemorrhage. For these reasons the policy assigns investigational status and aligns with technology-assessment and NICE guidance recommending use in research settings or with special arrangements.
Long-term observational data for sleeve gastrectomy indicate a notable incidence of de novo or worsened reflux and related pathology. In one long-term series, postoperative findings included new hiatal hernia in 45% and Barrett metaplasia in 15% of follow-up endoscopies, and conversions to RYGB for intractable reflux occurred. The study suggests that large preexisting hiatal hernia, GERD, and Barrett esophagus be considered relative contraindications to sleeve gastrectomy, while noting the study’s limited sample size and early experience.
The policy does not present blanket coverage exclusions in the cited excerpt but assigns investigational or unproven status to several procedures and devices based on evidence limitations. Notably, bariatric artery embolization (TBE/LGA embolization) is considered investigational due to small, heterogeneous studies and incomplete long-term safety data; gastric electrical stimulation and many transoral endoscopic techniques are similarly characterized as investigational or of insufficient evidence.
Other procedures noted as unproven or not medically necessary (or best considered investigational pending stronger evidence) include laparoscopic greater curvature plication (LGCP), silastic ring vertical gastric bypass (SRVGB) where device-specific complications and lack of standardized technique raise concerns, and various endoscopic bariatric therapies that have not demonstrated greater weight loss than bariatric surgery and lack long-term comparative data.
NICE and other guideline sources cited by the policy recommend restricting some devices (e.g., DJBL/EndoBarrier, swallowable gastric balloon) to research settings or special arrangements and advise caution with newer single-anastomosis or device-driven procedures until more robust long-term evidence is available.
The policy identifies a range of procedures and devices described in the evidence as investigational or unproven and explains the rationale for their classification. Examples include: Transcatheter bariatric embolization (left gastric artery embolization), where small RCTs and case series show short-term weight effects but insufficient durability and safety characterization; gastric electrical stimulation, with early-phase feasibility data but no high-quality comparative trials establishing long-term efficacy; and LGCP, which pooled analyses show to be inferior to sleeve gastrectomy with higher adverse events and revision rates.
Endoscopic bariatric procedures such as ESG and intragastric balloons produce greater weight loss than lifestyle modification but consistently less weight loss than standard surgical options (LSG), and device-specific safety profiles (for example, high early removal and SAE rates with DJBL) weigh against routine coverage absent stronger long-term randomized evidence.
The policy lists procedures characterized as investigational or not medically necessary and provides the supporting evidence-based rationale. For instance, pooled and comparative studies indicate that LGCP yields less effective and less durable weight loss compared with LSG and is associated with higher adverse event and revision rates—supporting its classification as unproven relative to standard procedures.
Similarly, endoscopic techniques (including ESG, intragastric balloons, and other transoral approaches) have limited RCT evidence, short-term follow-up, and variable safety profiles; they are not shown to provide greater weight loss than established bariatric surgeries, which informs the policy’s cautious stance and investigational classification for many of these technologies.
Evidence summaries in the policy emphasize that many endoscopic bariatric procedures produce less weight loss than surgical sleeve gastrectomy and that long-term durability and comparative effectiveness remain uncertain. Systematic reviews and meta-analyses report ESG TBWL ranges substantially lower than LSG at 6–12 months and pooled serious adverse event rates generally low but variable across analyses.
Device-specific risks are highlighted—for example, gastrointestinal liners (DJBL) show early removal rates around 19% and SAE rates of approximately 17%, and VBLOC did not meet prespecified efficacy objectives in the ReCharge randomized sham-controlled trial. These findings guide the policy’s recommendation that some devices be limited to research settings or considered investigational until higher-quality long-term evidence is available.
VBLOC (vagal nerve blocking/Maestro system) is discussed with reference to the ReCharge pivotal randomized sham-controlled trial. The trial met its primary safety endpoint but did not meet prespecified coprimary efficacy objectives versus sham; although some open-label studies report modest EWL at 24 months, the lack of consistent randomized long-term efficacy data underpins a cautious coverage stance for routine VBLOC use.
Given the ReCharge results and the limited supportive randomized long-term evidence, the policy indicates that VBLOC’s routine use is not supported and that prior authorization review should require detailed documentation of prior conservative therapy, BMI/comorbidity status, and informed consent acknowledging uncertain long-term benefit.
The policy captures evidence considerations relevant to coverage determinations: endoscopic procedures such as ESG and intragastric balloons demonstrate short-term weight loss benefits compared with lifestyle modification but generally less weight loss than LSG; device safety profiles vary considerably and some devices have notable SAE signals (e.g., DJBL).
Because most studies are observational or have short follow-up, the policy emphasizes the need for larger randomized trials with longer-term outcomes before considering routine coverage for many newer or device-specific bariatric therapies. Where devices meet guideline-informed thresholds and have appropriate regulatory approval, coverage may be considered within structured multidisciplinary programs with defined follow-up and documentation requirements.
The policy explicitly identifies bariatric artery embolization as investigational/unproven. Supporting evidence includes a small sham-controlled RCT showing greater TBWL at 6 months with TBE but an overall evidence base composed largely of small case series and limited follow-up. Safety concerns include procedure-related complications reported in case reports and series; larger controlled datasets with longer follow-up are needed to characterize safety and efficacy adequately.
As a result, TBE/LGA embolization is not supported for routine coverage outside of research contexts, and prior-authorization reviews may deny coverage for investigational procedures lacking sufficient evidence of long-term benefit and safety.
Laparoscopic greater curvature plication (LGCP) and silastic ring vertical gastric bypass (SRVGB) are discussed with attention to comparative effectiveness and safety. Meta-analyses and recent cohort data indicate LGCP is inferior to LSG for weight loss, associated with higher adverse events and revision rates, and shows poor long-term durability—supporting a noncoverage or investigational stance relative to established operations.
SRVGB has limited randomized evidence and device-specific late risks; the overall evidence quality is low and inconsistent, so SRVGB is not established as superior or equivalent to standard RYGB or sleeve gastrectomy, and the policy treats it cautiously pending more robust RCTs and standardized technique reporting.
Endoscopic bariatric therapies (EBTs) and intragastric balloons receive detailed evidence and guideline-aligned consideration. Systematic reviews and evidence-assessment reports show that EBTs (including ESG and various IGBs) produce greater weight loss than lifestyle modification but less than surgical sleeve gastrectomy, with pooled serious adverse event rates generally low but device-dependent.
Guideline and technology-assessment sources (for example, ASGE/AGA PIVI assessments and NICE guidance) inform that some EBTs may meet predefined thresholds for short-term weight loss and safety, but the policy requires that such therapies be delivered with multidisciplinary support, structured lifestyle programs, and clear documentation of prior conservative therapy; procedures without robust long-term evidence are considered investigational or limited to research settings.
Coverage criteria in the policy are mapped to guideline recommendations: candidates for metabolic and bariatric surgery should meet established BMI/comorbidity thresholds (for example, adult criteria such as BMI ≥40 kg/m2 or BMI 35–39.9 kg/m2 with qualifying comorbidity, and adjusted thresholds for certain ethnic groups). Prior authorization and medical-record review are expected to confirm that patients meet these guideline-based thresholds and that multidisciplinary evaluation and referral to experienced centers occurred.
For adolescents, the policy aligns with pediatric society guidance requiring multidisciplinary assessment, family psychosocial evaluation, and age/biologic-maturity considerations; documentation requirements for adolescents were updated to include obesity class and other adolescent-specific items in the medical-record checklist.
Guideline-informed considerations are summarized to guide coverage decisions: patient selection should follow society-recommended BMI and comorbidity thresholds, candidates must agree to long-term follow-up, and certain groups (e.g., preadolescent children, pregnant or breastfeeding adolescents, or patients with unresolved substance use, untreated psychiatric disorders, or active eating disorders) should be excluded from surgical consideration per Endocrine Society and other guidelines.
Regulatory and technology-assessment guidance (for example, NICE) recommends use of specific devices only in research or under special governance arrangements when evidence is limited; the policy advises that coverage decisions should reflect these guideline elements and evidence-quality limitations, and that procedures with insufficient evidence should be considered investigational or limited to research contexts.
Applicable Procedure Codes, Thresholds, and Key Metrics
| 0813T | Esophagogastroduodenoscopy, flexible, transoral, with volume adjustment of intragastric bariatric balloon. |
| 43290 | Esophagogastroduodenoscopy, flexible, transoral; with deployment of intragastric bariatric balloon. |
| 43291 | Esophagogastroduodenoscopy, flexible, transoral; with removal of intragastric bariatric balloon(s). |
| 43644 | Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less). |
| 43645 | Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption. |
| 43647 | Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum. |
| 43648 | Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum. |
| 43659 | Unlisted laparoscopy procedure, stomach. |
| 43770 | Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (e.g., gastric band and subcutaneous port components). |
| 43771 | Laparoscopy, surgical, gastric restrictive procedure; revision of adjustable gastric restrictive device component only. |
| 0813T | Esophagogastroduodenoscopy, flexible, transoral, with volume adjustment of intragastric bariatric balloon. |
| 43290 | Esophagogastroduodenoscopy, flexible, transoral; with deployment of intragastric bariatric balloon. |
| 43291 | Esophagogastroduodenoscopy, flexible, transoral; with removal of intragastric bariatric balloon(s). |
| 43644 | Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less). |
| 43645 | Laparoscopy, surgical, gastric restrictive procedure; with small intestine reconstruction to limit absorption. |
| 43647 | Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum. |
| 43648 | Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum. |
| 43659 | Unlisted laparoscopy procedure, stomach. |
| 43770 | Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (e.g., gastric band and subcutaneous port components). |
| 43771 | Laparoscopy, surgical, gastric restrictive procedure; revision of adjustable gastric restrictive device component only. |
| 43843 | Laparoscopy, surgical, gastric restrictive procedure; longitudinal gastrectomy (i.e., sleeve gastrectomy). |
| 43846 | Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit absorption (biliopancreatic diversion with duodenal switch). |
| 43848 | Revision, open, of gastric restrictive procedure for morbid obesity, other than adjustable gastric restrictive device (separate procedure). |
| 43860 | Revision of gastrojejunal anastomosis (gastrojejunostomy) with reconstruction, with or without partial gastrectomy or intestine resection; without vagotomy. |
| 43881 | Implantation or replacement of gastric neurostimulator electrodes, antrum, open. |
| 43882 | Revision or removal of gastric neurostimulator electrodes, antrum, open. |
| 43886 | Gastric restrictive procedure, open; revision of subcutaneous port component only. |
| 43887 | Gastric restrictive procedure, open; removal of subcutaneous port component only. |
| 43888 | Gastric restrictive procedure, open; removal and replacement of subcutaneous port component only. |
| 43889 | Gastric restrictive procedure, transoral, endoscopic sleeve gastroplasty (ESG), including argon plasma coagulation, when performed. |
| 43889 | Added to list of applicable CPT codes (description not present in this extract). |
Prior Authorization, Documentation, and Authorization Guidance
Medical records and preoperative documentation required
Provide medical records demonstrating: indication that the requested procedure is initial, planned two‑stage, revision, or removal; completion of a preoperative evaluation including detailed weight history and dietary and physical activity patterns; psychosocial‑behavioral evaluation or participation in a multidisciplinary surgical preparatory regimen (including nutrition consult); current and two‑year BMI history; documentation of treatments tried, failed, or contraindicated with dates/duration/reason; results of recent relevant diagnostic testing; physician's treatment plan; and for adolescents (12–17 years) include obesity class. For subsequent bariatric surgery also include date of initial surgery, details of complications (if any), and the complete staged surgical plan.
- Indicate whether request is for initial, planned two‑stage procedure, revision, or removal.
- Preoperative evaluation: detailed weight history, dietary and physical activity patterns.
- Psychosocial‑behavioral evaluation or participation in a multidisciplinary surgical preparatory regimen (including nutrition consult).
- Current and two‑year BMI history.
- Documentation of treatments tried, failed, or contraindicated (include dates, duration, reason).
- Results of recent relevant diagnostic testing.
- Physician's treatment plan.
- For adolescents 12–17: include obesity class.
- For subsequent bariatric surgery: date of initial surgery, details of complications, and complete staged surgical plan.
Reference CPT/unlisted codes on authorization requests
When requesting authorization, reference the applicable CPT and unlisted procedure codes listed in the policy (e.g., 0813T, 43290, 43291, 43644, 43645, 43647–43659, 43770–43775, 43843–43848, 43860, 43881–43889, 64590, 64595, 64999). Inclusion of a code is for reference only and does not by itself authorize coverage; indicate procedure type requested (initial, two‑stage, revision, removal).
- List the applicable CPT/unlisted codes from the policy when submitting an authorization request.
- Indicate procedure type: initial, planned two‑stage, revision, or removal.
- Note: code listing is reference only and does not guarantee coverage.
Document multidisciplinary assessment and clear indication for revisional surgery
Prior authorization for revisional bariatric surgery must include documentation of a multidisciplinary assessment and clear indication for revision (distinguish anatomical/technical failure from behavioral causes), plus prior measures attempted (diet/lifestyle/pharmacologic) and the rationale for the chosen revisional procedure.
- Provide multidisciplinary assessment findings and risk‑benefit consideration prior to revision.
- Document whether inadequate weight loss/weight regain is due to anatomical causes versus behavioral nonadherence.
- List prior conservative measures and prior bariatric procedures with dates and complications.
Prior authorization documentation required for revisional bariatric surgery
Prior authorization is required for revisional bariatric procedures and should include the indication for revision, prior weight‑loss trajectory, documentation of failure or complications of the primary surgery, prior procedure type and dates, and the rationale that establishes medical necessity for the revisional operation.
- Include indication, prior weight‑loss trajectory, and documented failure or complications.
- Provide prior procedure type, date(s), and operative details.
- Explain rationale for selected revisional technique to demonstrate medical necessity.
Acknowledge higher revision risk and provide supporting evidence for revisional requests
Revisional procedures are commonly required after failed primary operations (notably after LAGB); prior authorization should acknowledge that revisional surgery is associated with variable outcomes and higher complication/reoperation rates and include evidence supporting the need for revision.
- State prior index procedure type (e.g., LAGB) and why revision is needed.
- Provide evidence of prior management and justification given higher complication and reoperation rates in revisional cases.
- Include multidisciplinary review documenting individualized risk assessment.
Prior authorization scrutiny expected for OAGB/MGB
Expect prior authorization scrutiny for one‑anastomosis/mini‑gastric bypass (OAGB/MGB); authorization should document indication, prior bariatric history, BMI/comorbidity status, and informed‑consent discussion addressing evolving evidence and higher reported rates of de novo GERD and marginal ulcers in some analyses.
- Document indication and prior bariatric history.
- Provide BMI and comorbidity status per guideline thresholds.
- Include informed‑consent discussion of uncertain long‑term outcomes and specific risks (e.g., de novo GERD, marginal ulcers).
Require PA for single‑anastomosis/hypoabsorptive procedures (SADI‑S/SADS)
Prior authorization is recommended for single‑anastomosis/hypoabsorptive procedures (e.g., SADI‑S/SADS); requests should include indication, prior bariatric history, informed‑consent discussion of uncertain long‑term risks, and documentation of plan for nutritional monitoring given limited long‑term evidence.
- Provide indication and prior bariatric procedures with dates.
- Document informed consent that describes limited long‑term evidence and potential nutritional risks.
- Include plan for postoperative monitoring and supplementation.
Confirm prior conservative management and follow‑up readiness for ESG/IGB
Prior authorization should confirm documented prior unsuccessful nonsurgical weight‑loss attempts and readiness for follow‑up when requesting endoscopic procedures (ESG) or intragastric balloons — trials generally required prior failure of conservative management and adherence to dietary restrictions and follow‑up.
- Document history of nonsurgical weight‑loss attempts and programs and duration.
- Confirm adherence to required dietary restrictions and scheduled follow‑up.
- Provide evidence of enrollment/participation in multidisciplinary support during device/procedure period.
Require PA and informed‑consent details for VBLOC
Prior authorization is advised for VBLOC (vagal nerve block) devices; authorization should document prior conservative weight‑loss attempts, BMI/comorbidity status, and informed consent acknowledging mixed efficacy and limited long‑term randomized data.
- Document prior conservative management and BMI/comorbidity eligibility.
- Provide informed‑consent discussion addressing ReCharge trial results and uncertain long‑term benefit.
- Include plan for follow‑up and outcome monitoring.
Verify guideline‑based eligibility and multidisciplinary referral in PA
Prior authorization must confirm guideline‑based eligibility (BMI thresholds and qualifying comorbidities) and that the candidate was evaluated by or referred to a multidisciplinary/expert MBS center as applicable.
- Confirm BMI and qualifying comorbidities meet ASMBS/NICE/AAP criteria.
- Document multidisciplinary evaluation or referral to an experienced MBS center.
- For adolescents, document family psychosocial assessment and center expertise.
Document candidacy thresholds and agreement to long‑term follow‑up
Authorization requires documentation that the patient meets BMI/comorbidity candidacy thresholds (e.g., BMI ≥40, or BMI 35–39.9 with significant comorbidity) and agrees to long‑term follow‑up; include evidence of agreement to postoperative monitoring.
- Document BMI and qualifying comorbidity per policy thresholds.
- Document patient agreement to necessary long‑term follow‑up.
- Include plan for postoperative surveillance and management.
Cite guidelines that underpin PA clinical criteria
Guideline and evidence references (ASMBS, AAP, NICE, MBSAQIP, ECRI, Hayes) inform prior authorization expectations and clinical criteria; these sources are cited to support PA clinical requirements though the chunks do not list additional submission items beyond documentation already specified.
- PA clinical criteria are informed by guideline sources cited in the policy.
- References support BMI thresholds, multidisciplinary evaluation, and documentation expectations.
- Sources do not add separate PA forms but inform the required clinical documentation.
Use updated CPT list and indicate procedure type on PA requests
Prior authorization requirements were updated and the applicable CPT code list revised (CPT 43889 was added); authorization requests should indicate the procedure type (initial, planned two‑stage, revision, removal) and include the updated medical‑record documentation described in the policy.
- Use the updated applicable CPT list (note addition of 43889).
- Indicate whether request is initial, planned two‑stage, revision, or removal.
- Attach the updated documentation set required for review.
Document first‑line non‑surgical therapy attempts
Conservative (first‑line) therapies — diet, physical activity, behavior modification, and medication management — should be documented as tried before surgical options when applicable; provide records of program participation and outcomes.
- Document types and duration of nonsurgical treatments tried (diet, exercise, behavioral programs, medications).
- Provide evidence of program participation and outcomes where relevant to PA.
Document conservative therapy and behavioral assessment prior to revision
Before revisional surgery for reflux or inadequate weight loss, document conservative measures attempted (diet/lifestyle modification and medical GERD management including acid‑reducing medications) and behavioral assessment results.
- Provide evidence of dietary and lifestyle interventions and medical GERD therapy trials.
- Document behavioral and medical evaluations addressing contributors to primary surgery failure.
Document staged surgical strategy and preconditions
For planned staged strategies, document the staged treatment plan (e.g., sleeve gastrectomy as first stage with planned second‑stage procedure within 2 years) and that the patient met the policy requirement of initial BMI ≥50 when applicable and adherence to nutrition/exercise.
- Include planned staged surgical timeline and rationale.
- If staged approach invoked, show initial BMI (≥50 kg/m2 when required) and adherence to nutrition/exercise.
- Confirm medical necessity at time of second stage.
Perform and document behavioral assessment before revisional surgery
Before revision, document behavioral and medical contributors to primary surgery failure (eating/lifestyle behaviors, psychiatric evaluation) and evidence of engagement with the medical team, since behavioral causes must be distinguished from anatomical causes.
- Provide behavioral assessment findings and any psychiatric evaluation.
- Document engagement and adherence to recommended lifestyle/behavioral interventions.
- Distinguish anatomical causes from behavioral nonadherence in the record.
Prefer established restrictive procedures before LGCP; document justification if used
Policy notes that LGCP is inferior and less durable than standard procedures; prior authorization/coverage should favor established restrictive procedures (LSG/RYGB) before LGCP and document why LGCP is selected only if justified by individual patient factors.
- Document why established options (LSG/RYGB) are not appropriate or feasible if proposing LGCP.
- Provide evidence of discussion of comparative efficacy and risks with the patient.
- Include rationale and multidisciplinary concurrence for selecting LGCP.
Require established procedures or trial/registry participation before newer endoscopic techniques
For newer endoscopic techniques and devices, require either prior use of established surgical options or enrollment in clinical trials/registries; authorization should document trial enrollment or explicit rationale and informed consent when requesting coverage outside research settings.
- Document enrollment in an appropriate clinical trial or registry when applicable.
- If requesting coverage outside research, provide rationale why standard surgery is unsuitable and informed‑consent discussion of limited evidence.
- Attach procedural standardization and surgeon training details if available.
Document staged escalation of therapy when applicable
Consider a stepwise treatment pathway: document escalation from lifestyle modification to endoscopic therapies to surgical options as clinically appropriate, including prior outcomes at each step to justify progression.
- Provide records showing progression and results of prior interventions (lifestyle, endoscopic, then surgical).
- Document multidisciplinary team decisions supporting escalation.
Document conservative multidisciplinary interventions before surgery
Conservative multidisciplinary interventions (diet, activity, behavioral modification, pharmacotherapy) should be documented prior to surgery where indicated by guidelines; include participation records and duration.
- Document multidisciplinary conservative interventions and duration.
- Provide evidence of pharmacotherapy trials when relevant.
Document prerequisites for device/endoscopic therapies (multidisciplinary support, prior therapy failure)
For device or endoscopic therapy requests (IGB, ESG, etc.), document multidisciplinary support and follow‑up capability and show prior failure of conservative therapy; include device‑specific BMI eligibility where applicable.
- Document multidisciplinary team support and planned follow‑up.
- Show prior conservative therapy failure and duration.
- Confirm device‑specific BMI indications (e.g., Orbera BMI ≥30–≤40) per FDA labeling when applicable.
Confirm device‑specific BMI indications and prior conservative therapy
For devices such as intragastric balloons and adjustable gastric bands, supply documentation that the adult patient meets device‑specific BMI ranges and that conservative measures were attempted and failed; verify contraindications (e.g., bands contraindicated <18 years).
- Confirm device BMI indication (e.g., Orbera: BMI ≥30 and ≤40).
- Provide records of failed conservative measures and program participation.
- Check and document device‑specific contraindications (age, prior surgeries).
Include detailed preoperative and psychosocial documentation for PA
Supply preoperative and psychosocial documentation: obesity‑focused history, prior weight‑loss attempts/programs, assessment of comorbidities, psychosocial‑behavioral evaluation, and participation in a multidisciplinary preparatory regimen as required for PA review.
- Include obesity‑focused history and physical exam elements.
- List prior weight‑loss attempts, programs, and maximal sustained weight loss.
- Attach psychosocial‑behavioral evaluation or documentation of multidisciplinary preparatory participation.
Use policy code list for claim submissions (reference only)
When submitting claims, reference the policy's listed CPT and unlisted codes for coding guidance; note that listing a code is reference only and does not guarantee coverage — verify member benefit and contractual requirements.
- Include the applicable CPT/unlisted code(s) on claims as referenced in the policy.
- Remember that code listing is for reference and does not assure coverage or reimbursement.
Provide detailed documentation distinguishing anatomical vs behavioral causes for revision
For revisional surgery authorization, document multidisciplinary assessment findings, explicitly identify whether inadequate weight loss/regain is anatomical vs behavioral, and include prior measures attempted and operative/complication history.
- Provide multidisciplinary assessment and risk/benefit analysis.
- Document anatomical findings (e.g., leak, obstruction) or behavioral causes with supporting evidence.
- Attach operative reports and prior complication details.
Include objective diagnostic confirmation for GERD‑driven revisional surgery
Objective diagnostic confirmation (for example, wireless Bravo pH monitoring) should be included when revisional surgery is for GERD or when objective testing was used to confirm reflux prior to conversion (e.g., LSG to RYGB).
- Attach objective testing results used to confirm GERD (e.g., pH monitoring reports).
- Include documentation that medical management for GERD was attempted prior to revisional surgery.
Attach operative details, prior procedure, weight trajectory, and complication history for revisional PA
Required documentation for revisional procedures includes operative details and indication for revision; prior procedure type and date; documentation of prior weight‑loss trajectory; and any complications necessitating revision.
- Operative report(s) and details of the planned revisional procedure.
- Date and type of the initial bariatric surgery.
- Weight‑loss trajectory before and after the index operation.
- Complications and interventions that justify revision.
Include baseline and follow‑up functional mobility testing for adolescents when available
For adolescents, include baseline functional mobility testing (e.g., 400‑m walk test) and follow‑up measurements used in outcome assessments when available to support the clinical record.
- Provide baseline 400‑m walk test results and follow‑up at 6, 12, and 24 months if available.
- Include reports of functional mobility and musculoskeletal pain assessments.
Document trial/procedure standardization and follow‑up details when applicable
When PA is informed by trial data or device pivotal studies, include trial/procedure details that reflect participant selection, standardization, surgeon training, follow‑up intervals, and outcome metrics if these data relate to the requested intervention.
- Attach relevant trial design or procedural standardization details if extrapolated to the patient's case.
- Document planned follow‑up intervals and outcome metrics aligned with trial protocols when applicable.
Include trial‑aligned follow‑up and prior trial‑style eligibility documentation
Clinical trial evidence and pivotal studies specify follow‑up intervals and outcomes (TBWL, EWL); include documentation of prior failed nonsurgical weight loss attempts and participation in lifestyle/diet programs as used in trials to support PA.
- Provide documentation of participation in supervised lifestyle/diet programs.
- Include prior failed nonsurgical attempts as documented in trial eligibility (dates/duration).
- State planned follow‑up intervals consistent with evidence standards.
Provide comprehensive preoperative obesity‑focused evaluation
Preoperative evaluation documentation should include a comprehensive obesity‑focused history, weight history, prior weight‑loss attempts and programs, assessment of comorbid conditions, and pertinent labs/diagnostics as recommended by guideline sources.
- Document obesity onset, severity, and recent weight trends.
- List prior weight‑loss attempts and physician‑supervised programs.
- Provide assessment of comorbidities and pertinent diagnostic testing/labs.
Document multidisciplinary adolescent evaluation and family psychosocial assessment
Adolescent PA must include multidisciplinary evaluation documentation addressing the patient and family (physical, psychosocial, social risk factors), family stability, and referral to an experienced pediatric MBS center.
- Include multidisciplinary assessment of patient and family and social risk factors.
- Document psychological evaluation of family stability as applicable.
- Confirm referral to or evaluation at an experienced pediatric MBS center.
Document preoperative psychological evaluation and counseling
Preoperative psychological evaluation by a licensed mental health provider experienced with severely obese patients is recommended and should be documented; include counseling on motivation, expectations, and behavioral readiness.
- Attach psychological evaluation report by a licensed mental health professional.
- Document counseling on expectations, motivation, and behavioral readiness.
- Note any identified psychiatric issues and management plans.
References that inform prior authorization clinical expectations
Use the policy references and guideline citations to support clinical decision‑making for PA reviews; these sources inform clinical thresholds and documentation expectations though they do not add separate submission items beyond those listed.
- Cited guidelines (ASMBS, AAP, NICE, MBSAQIP) underpin BMI thresholds and documentation expectations.
- References are for clinical support and do not replace required documentation items.
- Ensure submissions reference relevant guideline‑aligned clinical criteria when helpful.
Submit full medical records per updated documentation checklist
Provide complete medical records for review: indicate requested procedure type (initial/planned two‑stage/revision/removal); preoperative evaluation; physical activity patterns; recent diagnostic testing; physician's treatment plan; current and two‑year BMI history; treatments tried/failed/contraindicated (dates/duration/reason); and psychosocial behavioral evaluation or multidisciplinary preparatory participation.
- Indicate procedure requested and whether initial, planned two‑stage, revision, or removal.
- Attach preoperative evaluation, activity patterns, and recent diagnostic testing.
- Provide current and two‑year BMI history and treatments tried/failed/contraindicated with dates/duration/reason.
- Include psychosocial behavioral evaluation or proof of multidisciplinary preparatory regimen participation.
Insufficient documentation may cause denial
Insufficient medical-record documentation to demonstrate that the member meets the policy's clinical criteria may result in denial of coverage or delayed authorization.
- Ensure all required documentation elements are included; incomplete records risk denial.
- Follow the policy's updated medical‑record checklist to avoid insufficiency.
Code listing is reference only—verify benefits
Listing of a CPT or unlisted code in the policy does not by itself imply the service is covered; verify federal, state, and contractual benefit plan rules for coverage and reimbursement before submission.
- Confirm member benefit and contractual coverage prior to scheduling/claim submission.
- Do not assume coverage solely because a code appears in the policy's code list.
Thorough multidisciplinary preassessment required for revisional PA
Failure to document a thorough multidisciplinary preassessment and individualized risk/benefit consideration for revisional bariatric surgery can trigger denial or be considered insufficient justification for revision.
- Provide detailed multidisciplinary assessment and individualized risk/benefit analysis.
- Document alternatives tried and specific anatomical findings or complications prompting revision.
Evidence limitations for specific revisional procedures may trigger denials
Insufficient high‑quality evidence for certain revisional procedures (particularly after primary RYGB) may lead to denials; prior authorization should include strong clinical justification, outcomes expectations, and literature‑informed rationale when evidence is limited.
- Provide clear clinical justification and rationale when proposing revisional procedures with limited evidence.
- Include outcomes expectations and plan for monitoring and management of known risks.
Investigational procedures (e.g., LGA embolization) risk denial
Because procedures like bariatric artery embolization are investigational/unproven, requests for these interventions may be denied; document rationale and note that limited, heterogeneous evidence and uncertain long‑term safety were cited in the policy.
- Do not expect routine coverage for investigational procedures (e.g., LGA embolization); provide exceptional‑case justification if requested.
- Acknowledge evidence limitations and safety concerns when submitting requests.
Evidence insufficiency for newer endoscopic/single‑anastomosis procedures may lead to denial
Insufficient long‑term evidence for many endoscopic and newer single‑anastomosis procedures may lead to denial where long‑term safety/efficacy is required; include long‑term follow‑up and nutritional monitoring plans to address evidence gaps.
- Provide long‑term follow‑up plans and nutritional monitoring strategies for newer procedures.
- Document why standard options are unsuitable if requesting coverage outside research contexts.
Clinical Background and Procedural Definitions
Examples of specific devices and procedures discussed in the policy include gastrointestinal liners (EndoBarrier), multiple intragastric balloon systems, the TransPyloric Shuttle device, and several operative techniques and bypass variations. The policy summarizes device descriptions, regulatory status (for example, FDA approval of the TransPyloric Shuttle vs investigational status of EndoBarrier), and the available evidence for each listed intervention.
Policy Update Log
Replaced references to 'Nonalcoholic Fatty Liver Disease (NAFLD)' with 'Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)'.
Revised planned two-stage procedure criterion: changed wording from 'compliant with nutrition and exercise' to 'adherent to nutrition and exercise'.
Updated list of unproven and not medically necessary procedures and consolidated terminology (e.g., grouped gastrointestinal liners, intragastric balloons, and endoscopic sleeve gastroplasty under 'transoral endoscopic surgery').
Added CPT code 43889 to the list of applicable CPT codes as an annual code update.
Expanded and clarified required medical records documentation for reviews (added items such as indication of initial/planned two-stage/revision/removal, preoperative evaluation, physical activity patterns, recent diagnostic testing, physician treatment plan, adolescent obesity class) and replaced several prior documentation items (e.g., 5-year BMI history → 2-year BMI history).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.